Alzheimer's Drug Leqembi to be available in some areas in a few months https://politicaliq.com/2023/08/07/alzheimers-drug-leqembi-to-be-available-in-some-areas-in-a-few-months/ #Alzheimer #alzheimersdisease #Leqembi #FDA #Esai #Biogen #Medicare #politicaliq #news #politics
#alzheimer #alzheimersdisease #leqembi #FDA #esai #biogen #medicare #politicaliq #News #politics
Sage's new #antidepressant is more like an antibiotic than an SSRI: it's taken for 14 days, then re-dosed as needed. But its long-term effectiveness is debatable.
Turns out, it's so rapid-acting that some psychiatrists don't even care. But will the #FDA?
My preview ahead of the FDA decision:
www.statnews.com/2023/07/31/sage-zuranolone-antidepressant-fda/
#depression #sage #biogen #ssri #health #mentalhealth #healthcare #medicine #biotech #pharma
#antidepressant #FDA #depression #sage #biogen #ssri #health #mentalhealth #healthcare #medicine #biotech #pharma
#Biogen und Astra Zeneca kaufen zu
https://www.boersen-zeitung.de/unternehmen-branchen/biogen-und-astra-zeneca-kaufen-zu?utm_campaign=mastodon&utm_source=mastodon&utm_medium=Digital
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations —After FDA rejection, Gilead nears full EU nod for hep D drug — Judge orders J&J, talc opponents to engage in settlement talks -- See more on our front page news http://bit.ly/w28kSd #earnings #biogen #novartis #sanofi #gileadsciences #hepatitisd #legal #bankruptcy #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#earnings #biogen #novartis #Sanofi #gileadsciences #hepatitisd #legal #bankruptcy #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
US Senate kicks off fresh round of drug pricing control legislation —FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS—Novartis culls 10% of pipeline, doubles down on five core therapeutic areas-- See more on our front page news http://bit.ly/w28kSd #earnings #biogen #novartis #senate #legislation #drugpricing #als #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#earnings #biogen #novartis #senate #Legislation #drugpricing #ALS #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Busy with 3 program launches this year, Biogen trims pipeline —Novartis, helped by cost cuts, raises full-year outlook—Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO-- See more on our front page news http://bit.ly/w28kSd #earnings #biogen #novartis #jnj #consumerhealth #ipos #spinoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#earnings #biogen #novartis #jnj #consumerhealth #ipos #spinoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Four senior #FDA leaders forged close ties with #Biogen ahead of #Aduhelm's approval. Now they've all left FDA. Three of those four senior officials, who managed and worked closely with the clinical and biostats reviewers assigned to the Aduhelm application, have now ended up working at drugmakers
https://endpts.com/four-senior-fda-leaders-forged-close-ties-with-biogen-ahead-of-aduhelms-approval-now-theyve-all-left-fda/ #revolvingdoor #quidproquo
#fda #biogen #aduhelm #revolvingdoor #quidproquo
In another round of cuts, Biogen lays off unspecified number of employees — Big Pharma-partnered Evotec on high alert after cyber attack takes systems offline — Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus -- See more on our front page news http://bit.ly/w28kSd #biogen #layoffs #cybersecurity #cyberattack #clovisoncology #bankruptcy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#biogen #layoffs #cybersecurity #CyberAttack #clovisoncology #bankruptcy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Alzheimer's Association campaigns for broader Leqembi coverage — FDA reverses course; will hold adcomm for Sarepta’s DMD gene therapy— Pfizer and Astellas report positive data from prostate cancer therapy trial -- See more on our front page news http://bit.ly/w28kSd #alzheimers #eisai #biogen #fda #dmd #duchenne #pfizer #astellas #clinicaltrials #prostatecancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#alzheimers #eisai #biogen #FdA #dmd #Duchenne #pfizer #astellas #clinicaltrials #ProstateCancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Duchenne muscular dystrophy: major trials and events to watch in 2023 — Biogen gets EU court ruling in favor of blocking Tecfidera generic entry— FDA offers radio silence on question of spring Covid boosters -- See more on our front page news http://bit.ly/w28kSd #dmd #duchenne #fda #clinicaltrials #europe #generics #biogen #multiplesclerosis #ms #covid #covid19 #vaccines #boosters #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#dmd #Duchenne #FdA #clinicaltrials #europe #generics #biogen #multiplesclerosis #ms #covid #covid19 #vaccines #boosters #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#FDA will review #Eisai and #Biogen’s #Alzheimers treatment #Leqembi with decision on full approval expected in early July - https://www.cnbc.com/2023/03/06/alzheimers-fda-will-review-eisais-and-biogens-treatment-leqembi-with-decision-expected-in-july.html
#fda #eisai #biogen #alzheimers #leqembi
FDA sets July decision date for full approval of Leqembi — FDA widens Lilly's Verzenio breast cancer reach — Praxis shares fall 48% following mixed data for essential tremor candidate-- See more on our front page news http://bit.ly/w28kSd #fda #alzheimers #eisai #biogen #elililly #breastcancer #essentialtremor #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#FdA #alzheimers #eisai #biogen #elililly #breastcancer #essentialtremor #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo — FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label —Roivant ex-CEO Ramaswamy may be considering US Presidential run-- See more on our front page news http://bit.ly/w28kSd #gsk #vir #fda #aduhelm #biogen #alzheimers #roivant #vivekramaswamy #2024election #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#gsk #vir #FdA #aduhelm #biogen #alzheimers #roivant #vivekramaswamy #2024election #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023 — Astellas taps new CEO —Biogen and Sage get FDA priority review of depression med zuranolone -- See more on our front page news http://bit.ly/w28kSd #sanofi #earnings #druglaunches #astellas #ceos #biogen #sagetherapeutics #fda #depression #postpartumdepression #priorityreview #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#Sanofi #earnings #druglaunches #astellas #ceos #biogen #sagetherapeutics #FdA #depression #postpartumdepression #priorityreview #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
FDA considers major shift in COVID vaccine strategy — Biogen/ Ionis ALS therapy set for March FDA AdCom meeting — Merck KGaA shrinks U.S. research team as layoffs continue to batter industry -- See more on our front page news http://bit.ly/w28kSd #fda #covid #covid19 #vaccines #biogen #als #fda #merckkgaa #layoffs #researchanddevelopment #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#FdA #covid #covid19 #vaccines #biogen #ALS #merckkgaa #layoffs #researchanddevelopment #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting — Eisai learns from Biogen’s Aduhelm disaster —5 FDA decisions to watch in the first quarter -- See more on our front page news http://bit.ly/w28kSd #mergersandacquisitions #ipsen #astrazeneca #chiesi #jpm2023 #jpm23 #biogen #eisai #aduhelm #alzheimers #fda #pharma #pharmanews #biopharma #biotech #biotechnology #cafepharma
#mergersandacquisitions #ipsen #astrazeneca #chiesi #jpm2023 #jpm23 #biogen #eisai #aduhelm #alzheimers #FdA #pharma #pharmanews #biopharma #biotech #biotechnology #cafepharma
Wenn ich das lese, würde ich das Medikament trotz Zulassung nicht nehmen.
https://www.spiegel.de/wissenschaft/us-arzneibehoerde-vergibt-zulassung-fuer-alzheimer-medikament-a-ece261d4-9c24-413b-9581-cdd0a14f45c2#ref=rss?sara_ecid=soci_upd_wbMbjhOSvViISjc8RPU89NcCvtlFcJ
Lese ich zusätzlich, wie die Zulassung zustandegekommen ist, dann gleich gar nicht.
https://www.wsj.com/articles/biogen-aduhelm-fda-approval-congressional-investigation-11672333482
FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Enlarge / MRI of a human brain. (credit: Getty | BSIP)
The Foo... - https://arstechnica.com/?p=1908494 #cognitivedecline #alzheimers #treatment #antibody #approval #science #biogen #eisai #fda
#fda #eisai #biogen #science #approval #antibody #treatment #alzheimers #cognitivedecline
Ars Technica: FDA approves new Alzheimer’s treatment despite risks, unclear benefits https://arstechnica.com/?p=1908494 #Tech #arstechnica #IT #Technology #Cognitivedecline #Alzheimer's #treatment #antibody #approval #Science #Biogen #eisai #fda
#Tech #arstechnica #it #technology #cognitivedecline #alzheimer #Treatment #antibody #approval #science #biogen #eisai #fda
#FDA #corruption is nothing new #Biogen #Aduhelm
https://www.naturalnews.com/2023-01-05-fda-broke-protocol-collaborating-biogen-alzheimers-drug.html
#Aduhelm #biogen #corruption #FDA